Professor Kausik Ray - Mastering the Management of Hyperlipidemia in Statin-Treated or Statin-Intolerant Patients: Recent Treatment Advances for Patients That Remain at High Risk of ASCVD

Go online to PeerView.com/ZWU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Patients with atherosclerotic cardiovascular disease (ASCVD) are at high risk for future CV events. Hence, interventions such as lowering levels of low-density lipoprotein cholesterol (LDL-C) are indicated for reducing the risk of CV events and, in some populations, to reduce all-cause mortality. Despite the availability of national guidelines to inform the safe and effective use of lipid-lowering therapies, many patients with high-risk ASCVD fail to achieve their targeted LDL-C levels, especially in statin-treated or statin-intolerant high-risk patient populations. At a recent live web broadcast, a multidisciplinary panel of experts discussed the current perspectives and guidelines on hyperlipidemia management, explored the emerging role of newer nonstatin therapies including PCSK9-targeting agents, and gave practical insights on the possible use of these novel lipid-lowering agents to manage hyperlipidemia in high-risk patients with ASCVD. If you couldn't watch the live event, catch up with this on-demand version now! Upon completion of this activity, participants will be able to:Summarize recommendations offered in current treatment guidelines for the management of hyperlipidemia, both for primary and secondary prevention of cardiovascular events in patients with ASCVD, Assess available efficacy and safety data for current and emerging non-statin lipid-lowering agents in the setting of ASCVD, especially in patients on maximally tolerated doses of statin or statin-intolerant patients, Describe the mechanisms of action for newer lipid-lowering therapies to optimize treatment for patients on maximally tolerated doses of statin or statin-intolerant patients, Incorporate newer lipid-lowering therapies, alone or in combination, as appropriate, to provide guideline-directed LDL-C reduction and cardiovascular risk reduction in patients with high-risk ASCVD.